icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
gsFB7V3v9VSpfyQu
Listen
